Viridian Therapeutics, Inc.\DE (VRDN) stock forecast and price target
Price $30.87 · data as of November 13, 2026
12-month price target
Average target$42.19
Upside / downside+36.7%
Analysts16
ConsensusStrong buy
Low $33.00Average $42.19High $54.00
Gold marker: average target · white marker: today’s price ($30.87)
Analyst ratings
Strong buy 3Buy 14Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-3.51 | −5.6% | $75M |
| Next fiscal year ends December 31, 2027 | $-2.13 | +39.2% | $313M |
| Next quarter ends December 31, 2026 | $-0.74 | +31.7% | $49M |
| Quarter after ends March 31, 2027 | $-0.75 | +16.9% | $68M |
Consensus of the analysts covering Viridian Therapeutics, Inc.\DE, updated daily. In the last 30 days 5 estimates were raised and 1 lowered.
Frequently asked questions
What is the Viridian Therapeutics, Inc.\DE stock price target?
The average 12-month target from 16 analysts is $42.19, 36.7% above the current price of $30.87 Targets range from $33.00 to $54.00.
Is Viridian Therapeutics, Inc.\DE a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 14 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Viridian Therapeutics, Inc.\DE expected to earn?
Analysts expect EPS of $-3.51 for the fiscal year ending December 31, 2026 and $-2.13 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.